Positive News SentimentPositive NewsNASDAQ:AVDL Avadel Pharmaceuticals (AVDL) Stock Price, News & Analysis $16.72 +0.43 (+2.64%) (As of 07/26/2024 ET) Add Compare Share Share Today's Range$16.34▼$16.8250-Day Range$13.89▼$16.9152-Week Range$9.50▼$19.09Volume709,535 shsAverage Volume1.25 million shsMarket Capitalization$1.61 billionP/E RatioN/ADividend YieldN/APrice Target$24.57 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends Get Avadel Pharmaceuticals alerts: Email Address Avadel Pharmaceuticals MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside47.0% Upside$24.57 Price TargetShort InterestBearish12.52% of Shares Sold ShortDividend StrengthN/ASustainabilityN/ANews SentimentN/AInsider TradingN/AProj. Earnings GrowthGrowingFrom ($0.58) to $0.60 Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.1.80 out of 5 starsMedical Sector681st out of 936 stocksPharmaceutical Preparations Industry315th out of 436 stocks 3.5 Analyst's Opinion Consensus RatingAvadel Pharmaceuticals has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 7 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageAvadel Pharmaceuticals has only been the subject of 4 research reports in the past 90 days.Read more about Avadel Pharmaceuticals' stock forecast and price target. Previous Next 1.0 Short Interest Percentage of Shares Shorted12.52% of the outstanding shares of Avadel Pharmaceuticals have been sold short.Short Interest Ratio / Days to CoverAvadel Pharmaceuticals has a short interest ratio ("days to cover") of 9.4.Change versus previous monthShort interest in Avadel Pharmaceuticals has recently increased by 42.03%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldAvadel Pharmaceuticals does not currently pay a dividend.Dividend GrowthAvadel Pharmaceuticals does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for AVDL. Previous Next 2.7 News and Social Media Coverage News SentimentAvadel Pharmaceuticals has a news sentiment score of 1.81. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.61 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 1 news article for Avadel Pharmaceuticals this week, compared to 2 articles on an average week.Search InterestOnly 1 people have searched for AVDL on MarketBeat in the last 30 days. This is a decrease of -83% compared to the previous 30 days.MarketBeat FollowsOnly 2 people have added Avadel Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is a decrease of -33% compared to the previous 30 days. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Avadel Pharmaceuticals insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 4.80% of the stock of Avadel Pharmaceuticals is held by insiders.Percentage Held by Institutions69.19% of the stock of Avadel Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Avadel Pharmaceuticals' insider trading history. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Avadel Pharmaceuticals are expected to grow in the coming year, from ($0.58) to $0.60 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Avadel Pharmaceuticals is -8.99, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Avadel Pharmaceuticals is -8.99, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioAvadel Pharmaceuticals has a P/B Ratio of 17.06. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Avadel Pharmaceuticals' valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Paradigm PressMan who Predicted Trump 2016 Win: “Prepare for Election Meltdown”Former advisor to the CIA, the Pentagon and the White House Jim Rickards went on multiple TV news programs… A predicted Trump would win. You won’t believe what he’s predicting now.Click here to see it because it’s a SHOCKER… About Avadel Pharmaceuticals Stock (NASDAQ:AVDL)Avadel Pharmaceuticals plc operates as a biopharmaceutical company in the United States. Its lead product candidate is LUMRYZ, a formulation of sodium oxybate, which is in a Phase 3 clinical trial for the treatment of excessive daytime sleepiness or cataplexy in adults with narcolepsy. The company was formerly known as Flamel Technologies SA and changed its name to Avadel Pharmaceuticals plc in January 2017. Avadel Pharmaceuticals plc was incorporated in 2015 and is headquartered in Dublin, Ireland.Read More AVDL Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart AVDL Stock News HeadlinesJune 27, 2024 | globenewswire.comAvadel Pharmaceuticals to Join Russell 3000® IndexJune 16, 2024 | seekingalpha.comAvadel Pharmaceuticals: Inflection Point AheadJuly 27, 2024 | The Oxford Club (Ad)Man Who Called Nvidia at $1.10 Says Buy This Now...In 2004, one man called Nvidia before just about anyone knew it existed. Now, this same guy says a new company could become the next to soar like Nvidia.May 30, 2024 | globenewswire.comAvadel Pharmaceuticals to Present at Upcoming Investor ConferencesMay 22, 2024 | finanznachrichten.deAvadel Pharmaceuticals plc: Avadel Pharmaceuticals Shares New LUMRYZ (sodium oxybate) For Extended-release Oral Suspension (CIII) Data at SLEEP 2024May 22, 2024 | finance.yahoo.comAvadel Pharmaceuticals Shares New LUMRYZ™ (sodium oxybate) For Extended-release Oral Suspension (CIII) Data at SLEEP 2024May 22, 2024 | globenewswire.comAvadel Pharmaceuticals Shares New LUMRYZ™ (sodium oxybate) For Extended-release Oral Suspension (CIII) Data at SLEEP 2024May 21, 2024 | globenewswire.comAvadel Pharmaceuticals Appoints Naseem Amin, M.D. to its Board of DirectorsJuly 27, 2024 | The Oxford Club (Ad)Man Who Called Nvidia at $1.10 Says Buy This Now...In 2004, one man called Nvidia before just about anyone knew it existed. Now, this same guy says a new company could become the next to soar like Nvidia.May 13, 2024 | msn.comAvadel gains for a second day as analysts see it prevailing in case vs Jazz/FDAMay 10, 2024 | markets.businessinsider.comBuy Rating Affirmed for Avadel Pharmaceuticals Amidst Strong Growth Potential and Market ExpansionMay 9, 2024 | finance.yahoo.comAvadel Pharmaceuticals plc (NASDAQ:AVDL) Q1 2024 Earnings Call TranscriptMay 8, 2024 | msn.comAvadel Pharmaceuticals GAAP EPS of -$0.30 misses by $0.29, revenue of $27.18M beats by $1.28MMay 8, 2024 | investorplace.comAVDL Stock Earnings: Avadel Pharmaceuticals Misses EPS, Beats Revenue for Q1 2024May 8, 2024 | finanznachrichten.deAvadel Pharmaceuticals plc: Avadel Pharmaceuticals Provides Corporate Update and Reports First Quarter 2024 Financial ResultsMay 8, 2024 | finance.yahoo.comAvadel Pharmaceuticals Reports First Quarter 2024 Earnings: Revenue Surpasses Estimates but Net ...May 8, 2024 | globenewswire.comAvadel Pharmaceuticals Provides Corporate Update and Reports First Quarter 2024 Financial ResultsMay 1, 2024 | globenewswire.comAvadel Pharmaceuticals to Provide a Corporate Update and Report First Quarter 2024 Financial Results on May 8See More Headlines Receive AVDL Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Avadel Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/08/2024Today7/26/2024Next Earnings (Estimated)8/14/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:AVDL CUSIPN/A CIK1012477 Webwww.avadel.com Phone(531) 901-5201Fax353-1526-1077Employees70Year Founded2015Price Target and Rating Average Stock Price Target$24.57 High Stock Price Target$29.00 Low Stock Price Target$21.00 Potential Upside/Downside+47.0%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage7 Analysts Profitability EPS (Most Recent Fiscal Year)($1.86) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-160,280,000.00 Net Margins-284.42% Pretax Margin-284.11% Return on Equity-139.72% Return on Assets-79.53% Debt Debt-to-Equity RatioN/A Current Ratio2.85 Quick Ratio2.60 Sales & Book Value Annual Sales$27.96 million Price / Sales57.48 Cash FlowN/A Price / Cash FlowN/A Book Value$0.98 per share Price / Book17.06Miscellaneous Outstanding Shares96,120,000Free Float91,505,000Market Cap$1.61 billion OptionableOptionable Beta1.52 Social Links The 10 Best AI Stocks to Own in 2024Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.Get This Free Report Key ExecutivesMr. Gregory J. Divis Jr. (Age 57)CEO & Director Comp: $985.2kMr. Thomas S. McHugh (Age 59)Senior VP, Principal Financial and Accounting Officer & CFO Comp: $663.14kMr. Richard J. Kim (Age 55)Chief Commercial Officer Comp: $770.95kMr. Jerad G. SeurerGeneral Counsel & Company SecretaryMr. Gregory J. Davis (Age 59)VP of Corporate and Business Development Mr. Mark W. ElrodVice President of SalesMs. Angie WoodsVice President of People & CultureDr. Jordan S. Dubow M.D. (Age 45)Consultant Comp: $727.93kDr. Jason M. VaughnSenior Vice President of Technical OperationsMs. Jennifer Gudeman PharmDSenior Vice President of Medical & Clinical AffairsMore ExecutivesKey CompetitorsCollegium PharmaceuticalNASDAQ:COLLBicycle TherapeuticsNASDAQ:BCYCBioDelivery Sciences InternationalNASDAQ:BDSIImmunicNASDAQ:IMUXOvid TherapeuticsNASDAQ:OVIDView All CompetitorsInsiders & InstitutionsBank of New York Mellon CorpBought 325,388 shares on 7/26/2024Ownership: 0.339%Iridian Asset Management LLC CTBought 45,675 shares on 7/26/2024Ownership: 0.122%Krilogy Financial LLCBought 17,262 shares on 7/22/2024Ownership: 0.018%Diversify Advisory Services LLCSold 19,267 shares on 7/12/2024Ownership: 0.014%Cetera Advisors LLCBought 7,531 shares on 5/24/2024Ownership: 0.096%View All Insider TransactionsView All Institutional Transactions AVDL Stock Analysis - Frequently Asked Questions How have AVDL shares performed this year? Avadel Pharmaceuticals' stock was trading at $14.12 at the start of the year. Since then, AVDL shares have increased by 18.4% and is now trading at $16.72. View the best growth stocks for 2024 here. How were Avadel Pharmaceuticals' earnings last quarter? Avadel Pharmaceuticals plc (NASDAQ:AVDL) released its quarterly earnings results on Wednesday, May, 8th. The company reported ($0.30) EPS for the quarter, missing analysts' consensus estimates of ($0.25) by $0.05. The company's revenue was up 2617.8% compared to the same quarter last year. Who are Avadel Pharmaceuticals' major shareholders? Avadel Pharmaceuticals' top institutional shareholders include Bank of New York Mellon Corp (0.34%), Iridian Asset Management LLC CT (0.12%), Krilogy Financial LLC (0.02%) and Diversify Advisory Services LLC (0.01%). Insiders that own company stock include Gregory J Divis, Eric J Ende, Thomas S Mchugh, Mark Anthony Mccamish, Geoffrey Michael Glass and Linda Palczuk. View institutional ownership trends. How do I buy shares of Avadel Pharmaceuticals? Shares of AVDL stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of Avadel Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some other companies that Avadel Pharmaceuticals investors own include Intelsat (I), Bank of America (BAC), Fossil Group (FOSL), Ciena (CIEN), AMC Entertainment (AMC), Chaarat Gold (CGH) and Associated British Foods (ABF). This page (NASDAQ:AVDL) was last updated on 7/27/2024 by MarketBeat.com Staff From Our Partners625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | Sponsored“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 sp...Unstoppable Prosperity | SponsoredNext opportunity for crypto millionsThe Bitcoin halving is the #1 creator of "crypto millionaires". That's because historically, every halving has...Crypto 101 Media | Sponsoredtop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)AI was by far the biggest tech investing trend right now. But Ross Givens says the #1 artificial intelligen...Traders Agency | SponsoredThe #1 Crypto for 2024 (3 Cent Coin)Chris Rowe – the man who recommended Amazon in 1998… Bitcoin and Ethereum in 2017… And has spotted 44 diffe...True Market Insiders | SponsoredThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-u...Weiss Ratings | SponsoredAlex's "Next Magnificent Seven" StocksToday Alex Green is releasing his new breakdown of AI's "Next Magnificent Seven." So please make some time ...The Oxford Club | SponsoredNEW AI developed by trader who won 1,129% (in 2 days)Earlier this year one legendary trader captured a 1,129% win (in just 2 days) ... LIVE in front of thousands o...Monument Traders Alliance | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Avadel Pharmaceuticals plc Please log in to your account or sign up in order to add this asset to your watchlist. Share Avadel Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
